Business
CardioComm Solutions Executes Servier Canada Supplier Agreement for Coordination of the Tempo In-Clinic Heart Failure ECG Monitoring Program
Toronto, Ontario--(Newsfile Corp. - November 20, 2017) - Established medical electrocardiogram...
About this update from Cardiocomm Solutions, Inc.
[{"type":"text","content":"CardioComm Solutions Executes Servier Canada Supplier Agreement for Coordination of the Tempo In-Clinic Heart Failure ECG Monitoring ProgramHeartCheck(TM) ECG Devices and GEMS(TM) Home Software Loan Program to Support ECG-Based Heart Rate MonitoringToronto, Ontario--(Newsfile Corp. - November 20, 2017) - Established medical electrocardiogram (\"ECG\") software and device manufacturer CardioComm Solutions, Inc. (TSXV: EKG) (\"CardioComm\" or the \"Company\") today confirmed it has entered into a supply and service agreement with Quebec-based Servier Canada Inc. (\"Servier\") for the coordination of a new handheld ECG monitor loan program. The three year program entitled \"TEMPO\" involves the loan of HeartCheck™ ECG monitors to approximately 120 cardiology clinics active in treating heart failure patients across Canada. The specific objective of TEMPO is to facilitate the taking of diagnostic-level, in-office ECG readings at busy practices to help improve the treatment of heart failure patients across the country. The TEMPO program will be supported in compliance with the Innovative Medicines Code of Ethical Practices. CardioComm was selected as the partner company due to the Company's unique profile as an FDA cleared, ISO certified, CE marked and Health Canada approved company since the Company can provide simple to use and accurate medical software and devices for use in both clinical and consumer markets. CardioComm is the manufacturer of the HeartCheck™ ECG devices and will act as the central point of contact for the participating cardiology clinics throughout the three year program. CardioComm will also be responsible for provisioning the HeartCheck™ devices, responding to all questions related to the HeartCheck™ device and for TEMPO program administration.CardioComm has been growing its position as a leader in the remote medical diagnostic monitoring industry in supporting hospitals, medical call centers, doctors' offices, patient monitoring and telemedicine platforms. The opportunity to support the pharmaceutical sector is a logical progression for CardioComm, as ECG monitoring is a critical element in clinical studies for the evaluation of new medications, as well as for launch and post-launch of approved medications that have cardio protective effects. CardioComm's technologies hold a unique m...